Arcus Biosciences, Inc.

RCUS

Arcus Biosciences, Inc.

RCUS

Insider Sentiment (TTM):

Last Purchase:2025-02-27Last Sale:2026-06-24Shares Purchased (TTM):0Shares Sold (TTM):397,042

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:118,327,804Shares Outstanding:125,400,000Institutional Ownership Pct.:94.36%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	150	201	222	238	248	192	150	201	156	185	127	184
Available For Sale Securities Debt Securities Curr…	552	621	759	593	663	805	828	888	813	810	632	615
Contract With Customer Asset Net Current	36	3	11	11	15	15	20	16	28	35	38	52
Prepaid Expense And Other Assets Current	18	19	15	15	20	19	18	22	25	34	34	31
Assets Current	756	844	1,007	857	946	1,031	1,016	1,127	1,022	1,064	831	882
Available For Sale Securities Debt Securities Nonc…	73	54	29	10	16	8	14	2	40	100	107	151
Property Plant And Equipment Net	36	38	40	42	44	46	47	48	49	51	51	50
Other Assets Noncurrent	59	61	63	65	69	71	73	75	75	78	106	108
Assets	924	997	1,139	974	1,075	1,156	1,150	1,252	1,186	1,293	1,095	1,191
Liabilities
Liabilities Current
Accounts Payable Current	34	39	42	42	29	22	18	13	15	16	17	17
Contract With Customer Liability Current	19	34	35	52	71	72	85	105	113	124	91	103
Other Liabilities Current	145	136	154	141	110	98	123	97	71	64	76	80
Liabilities Current	198	209	231	235	210	192	226	215	199	204	184	200
Contract With Customer Liability Noncurrent	37	45	43	53	60	219	234	289	214	242	307	326
Long Term Debt	101	100	99	98	97	48	48	47	-	-	0	-
Other Liabilities Noncurrent	124	119	135	152	159	166	157	136	138	140	142	145
Stockholders Equity
Preferred Stock Value	-	-	-	-	-	-	-	-	-	-	-	0
Common Stock Value	2,169	2,138	2,116	1,815	1,793	1,775	1,617	1,602	1,582	1,561	1,311	1,291
Retained Earnings Accumulated Deficit	-1,704	-1,613	-1,485	-1,379	-1,244	-1,244	-1,132	-1,038	-946	-853	-849	-768
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	-	-	-	-	-	1	-1	-1	0	-3
Stockholders Equity	464	524	631	436	549	531	485	565	635	707	462	520
Liabilities And Stockholders Equity	924	997	1,139	974	1,075	1,156	1,150	1,252	1,186	1,293	1,095	1,191
Related Party	-	11	0	-4	0	4	6	-12	-7	21	20	22
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	-	0
Preferred Stock Shares Authorized	-	-	-	-	-	-	-	-	-	-	-	10
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	-	-	0
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	127	126	125	107	106	106	92	92	91	91	76	75
Shares Outstanding	127	126	125	107	106	106	92	92	91	91	76	75

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.76%	18.96%	9.06%	-	-	-	-	-	-	-	-	-
2025	9.98%	-2.09%	25.99%	11.59%	35.30%	82.40%	10.92%	10.56%	9.66%	6.76%	19.63%	17.32%
2024	-1.25%	-0.20%	3.60%	25.05%	12.56%	19.21%	-1.84%	-2.92%	-16.34%	-12.70%	-23.05%	-16.41%
2023	-	-	-	16.42%	-1.43%	-21.31%	-2.31%	16.11%	-8.02%	15.66%	1.04%	1.83%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.82	4.04	4.36	3.65	4.50	5.37	4.50	5.24	5.14	5.22	4.52	4.41
Quick Ratio	3.73	3.95	4.29	3.58	4.41	5.27	4.42	5.14	5.01	5.05	4.33	4.26
Working Capital	558.00M	635.00M	776.00M	622.00M	736.00M	839.00M	790.00M	912.00M	823.00M	860.00M	647.00M	682.00M
Leverage & Debt
Debt to Equity	0.43	0.40	0.37	0.54	0.38	0.36	0.47	0.38	0.31	0.29	0.40	0.38
Interest Coverage TTM	-44.18	-39.80	-48.25	-46.88	-56.33	-109.00	-82.50	-106.00	-97.67	-90.00	-170.00	-323.00
Debt Ratio	0.21	0.21	0.20	0.24	0.20	0.17	0.20	0.17	0.17	0.16	0.17	0.17
Efficiency & Turnover
Asset Turnover TTM	0.12	0.22	0.22	0.22	0.23	0.12	0.23	0.22	0.21	0.19	0.10	0.09
Per Share Metrics
Diluted EPS TTM	-3.65	-2.94	-3.29	-3.20	-2.80	-3.97	-3.14	-2.95	-2.73	-2.68	-4.15	-3.93
Free Cash Flow Per Share TTM	-3.73	-3.92	-4.53	-3.13	-1.99	-3.08	-1.95	-1.85	-2.93	-2.73	-4.46	-4.10
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-415.38%	-168.64%	-156.28%	-156.25%	-129.01%	-309.22%	-127.91%	-120.91%	-118.62%	-113.92%	-290.60%	-269.17%
Net Profit Margin TTM	-393.16%	-156.36%	-142.91%	-142.08%	-113.74%	-277.30%	-109.69%	-102.66%	-100.81%	-97.47%	-262.39%	-244.17%
Growth Metrics
Net Revenue Growth (1Y)	-55.34%	67.38%	-4.26%	-8.75%	6.07%	-40.51%	120.51%	119.17%	104.13%	99.16%	4.46%	-72.26%
Net Income Growth (1Y)	54.36%	-5.63%	24.73%	26.30%	19.68%	69.26%	-7.82%	-7.85%	-13.24%	-17.20%	14.98%	-468.38%
EPS Growth (1Y)	29.88%	-25.95%	4.64%	8.39%	2.76%	48.28%	-24.29%	-24.79%	-30.29%	-29.88%	11.87%	-456.53%
Valuation Metrics
P/E TTM	-8.45	-7.34	-7.25	-4.25	-2.90	-1.98	-4.74	-5.18	-5.57	-7.05	-4.60	-4.57
P/B TTM	8.38	5.17	4.06	3.32	1.57	1.45	2.77	2.47	2.18	2.30	3.06	2.58
P/S TTM	33.23	11.48	10.36	6.04	3.30	5.48	5.20	5.31	5.62	6.87	12.08	11.16
Market Cap	3.89B	2.71B	2.56B	1.45B	863.65M	772.44M	1.34B	1.40B	1.39B	1.63B	1.41B	1.34B
Enterprise Value	3.84B	2.61B	2.44B	1.31B	712.65M	628.44M	1.24B	1.24B	1.23B	1.44B	1.29B	1.16B
Calculated Values
Free Cash Flow TTM	-470.00M	-491.00M	-486.00M	-333.00M	-211.00M	-303.00M	-176.00M	-169.00M	-267.00M	-235.00M	-330.00M	-306.00M
Net Debt	-49.00M	-101.00M	-123.00M	-140.00M	-151.00M	-144.00M	-102.00M	-154.00M	-156.00M	-185.00M	-127.00M	-184.00M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-24Sale

Owner: Jaen, Juan C.

Title: President

Shares: 6,431

Price/Share: $29.66

Value: $190,743.46

Shares Owned: 890,809

Relationship: Officer

Ownership: Indirect

2026-06-01Sale

Owner: Azoy, Alexander

Title: Chief Accounting Officer

Shares: 2,562

Price/Share: $25.77

Value: $66,022.74

Shares Owned: 39,581

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Goeltz, Ii Robert C.

Title: Chief Financial Officer

Shares: 7,763

Price/Share: $25.63

Value: $198,965.69

Shares Owned: 84,161

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: Jaen, Juan C.

Title: President

Shares: 31,823

Price/Share: $22.29

Value: $709,334.67

Shares Owned: 922,240

Relationship: Officer

Ownership: Indirect

2025-12-31Sale

Owner: Goeltz, Ii Robert C.

Title: Chief Financial Officer

Shares: 6,552

Price/Share: $23.38

Value: $153,185.76

Shares Owned: 67,924

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-24	Jaen, Juan C.	Officer	President	Indirect	Sale	6,431	29.66	$190,743.46	890,809	4
2026-06-01	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	2,562	25.77	$66,022.74	39,581	4
2026-05-11	Goeltz, Ii Robert C.	Officer	Chief Financial Officer	Direct	Sale	7,763	25.63	$198,965.69	84,161	4
2026-01-05	Jaen, Juan C.	Officer	President	Indirect	Sale	31,823	22.29	$709,334.67	922,240	4
2025-12-31	Goeltz, Ii Robert C.	Officer	Chief Financial Officer	Direct	Sale	6,552	23.38	$153,185.76	67,924	4
2025-12-18	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	4,343	22.25	$96,631.75	18,531	4
2025-12-17	Jaen, Juan C.	Officer	President	Direct	Sale	9,983	22.16	$221,223.28	346,012	4
2025-12-17	Jarrett, Jennifer	Officer	Chief Operating Officer	Direct	Sale	9,983	22.16	$221,223.28	193,024	4
2025-12-17	Rosen, Terry J	Director,Officer	Chief Executive Officer	Direct	Sale	25,744	22.16	$570,487.04	2,194,809	4
2025-12-17	Goeltz, Ii Robert C.	Officer	Chief Financial Officer	Direct	Sale	5,960	22.16	$132,073.60	74,476	4
2025-12-17	Markus, Richard	Officer	Chief Medical Officer	Direct	Sale	4,494	22.16	$99,587.04	65,647	4
2025-12-17	Tang, Carolyn C.	Officer	General Counsel	Direct	Sale	6,810	22.16	$150,909.60	124,734	4
2025-12-04	Jaen, Juan C.	Officer	President	Indirect	Sale	82,997	24.71	$2,050,855.87	954,063	4
2025-11-26	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	1,900	26.00	$49,400.00	27,363	4
2025-11-26	Goeltz, Ii Robert C.	Officer	Chief Financial Officer	Direct	Sale	5,000	25.00	$125,000.00	87,138	4
2025-11-18	Jaen, Juan C.	Officer	President	Indirect	Sale	5,050	19.75	$99,737.50	1,037,060	4
2025-11-07	Jarrett, Jennifer	Officer	Chief Operating Officer	Direct	Sale	50,291	18.97	$954,020.27	214,232	4
2025-10-30	Jaen, Juan C.	Officer	President	Indirect	Sale	4,314	20.32	$87,660.48	1,087,060	4
2025-10-29	Jaen, Juan C.	Officer	President	Indirect	Sale	77,840	21.35	$1,661,884.00	1,091,374	4
2025-10-28	Goeltz, Ii Robert C.	Officer	Chief Financial Officer	Direct	Sale	5,000	20.00	$100,000.00	92,138	4
2025-10-08	Jarrett, Jennifer	Officer	Chief Operating Officer	Direct	Sale	37,792	15.05	$568,769.60	214,232	4
2025-09-29	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	2,831	13.00	$36,803.00	27,363	4
2025-09-05	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	1,579	11.88	$18,758.52	30,194	4
2025-02-27	Kaneko, Yasunori	Director	-	Direct	Purchase	20,000	10.06	$201,200.00	28,400	4
2025-02-27	Rosen, Terry J	Director,Officer	Chief Executive Officer	Direct	Purchase	19,800	10.18	$201,564.00	2,554,160	4
2025-02-18	Gilead, Sciences, Inc.	TenPercentOwner	-	Direct	Purchase	1,363,636	11.00	$14,999,996.00	31,424,760	4
2024-12-31	Goeltz, Ii Robert C.	Officer	Chief Financial Officer	Direct	Sale	3,594	15.00	$53,910.00	60,138	4
2024-12-02	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	201	15.32	$3,079.32	19,070	4
2024-08-13	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	1,357	14.97	$20,314.29	19,070	4
2024-03-27	Jarrett, Jennifer	Officer	Chief Operating Officer	Direct	Sale	11,551	17.55	$202,720.05	215,253	4
2024-03-18	Jarrett, Jennifer	Officer	Chief Operating Officer	Direct	Sale	13,449	18.23	$245,175.27	226,804	4
2024-02-27	Jaen, Juan C.	Officer	President	Indirect	Sale	23,132	20.10	$464,953.20	1,188,233	4
2024-02-27	Jarrett, Jennifer	Officer	Chief Operating Officer	Direct	Sale	34,070	20.11	$685,147.70	240,253	4
2024-01-29	Gilead, Sciences, Inc.	TenPercentOwner	-	Direct	Purchase	15,238,095	21.00	$319,999,995.00	30,061,124	4
2024-01-02	Jaen, Juan C.	Director,Officer	President	Indirect	Sale	6,975	20.09	$140,127.75	1,215,265	4
2024-01-02	Goeltz, Ii Robert C.	Officer	Chief Financial Officer	Direct	Sale	2,004	20.00	$40,080.00	51,831	4
2023-12-22	Jarrett, Jennifer	Director,Officer	Chief Operating Officer	Direct	Sale	21,521	17.76	$382,212.96	258,878	4
2023-12-01	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	282	14.95	$4,215.90	11,596	4
2023-09-22	Jarrett, Jennifer	Director,Officer	Chief Operating Officer	Direct	Sale	21,369	19.99	$427,166.31	302,691	4
2023-07-28	Jarrett, Jennifer	Director,Officer	Chief Operating Officer	Direct	Sale	45,000	20.25	$911,250.00	336,566	4
2023-07-03	Azoy, Alexander	Officer	Chief Accounting Officer	Direct	Sale	1,018	20.41	$20,777.38	11,596	4
2023-06-28	Gilead, Sciences, Inc.	TenPercentOwner	-	Direct	Purchase	1,010,000	19.26	$19,452,600.00	14,823,029	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

94.36%

Inst. Shares: 118,327,804

Shares Outstanding: 125,400,000

2025-12-31

110.84%

Inst. Shares: 119,041,695

Shares Outstanding: 107,400,000

2025-09-30

92.62%

Inst. Shares: 98,644,568

Shares Outstanding: 106,500,000

2025-06-30

91.80%

Inst. Shares: 97,399,524

Shares Outstanding: 106,100,000

2025-03-31

95.98%

Inst. Shares: 94,444,393

Shares Outstanding: 98,400,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	118,327,804	125,400,000	94.36%
2025-12-31	119,041,695	107,400,000	110.84%
2025-09-30	98,644,568	106,500,000	92.62%
2025-06-30	97,399,524	106,100,000	91.80%
2025-03-31	94,444,393	98,400,000	95.98%
2024-12-31	81,495,217	90,100,000	90.45%
2024-09-30	51,457,854	91,400,000	56.30%
2024-06-30	50,123,510	91,100,000	55.02%
2024-03-31	51,197,738	86,200,000	59.39%
2023-12-31	51,033,288	74,000,000	68.96%
2023-09-30	50,694,192	74,600,000	67.95%
2023-06-30	50,924,165	73,200,000	69.57%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Arcus Biosciences, Inc. (RCUS) — SEC Financial Statements & Analysis

Arcus Biosciences, Inc. (RCUS) is a pharmaceutical preparations company, incorporated in DE. Arcus Biosciences, Inc. trades on NYSE as: RCUS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Arcus Biosciences, Inc. reported a -55.34% year-over-year revenue growth, a Debt-to-Equity ratio of 0.43x, a Price-to-Sales (P/S) ratio of 33.23x (TTM), a Price-to-Book (P/B) ratio of 8.38x (TTM), at a market cap of $3.89B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -55.34%
Debt To Equity: 0.43x
P/S TTM: 33.23x
P/B TTM: 8.38x
Market Cap: $3.89B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Arcus Biosciences, Inc. in?

Arcus Biosciences, Inc. (RCUS) operates in the Pharmaceutical Preparations industry.

What is RCUS's market cap?

Arcus Biosciences, Inc. (RCUS) has a market capitalization of $3.89B as of 2026-06-30.

What exchange does RCUS trade on?

Arcus Biosciences, Inc. (RCUS) trades on the NYSE.

Where is Arcus Biosciences, Inc. incorporated?

Arcus Biosciences, Inc. is incorporated in DE.